Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06410261 · ClinicalTrials.gov registry record · NA

Exercise Rehabilitation Program in MS Who Use Wheelchairs as a Primary Mobility Device

A NA study of Multiple Sclerosis, sponsored by University of Illinois at Chicago.

Recruiting
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT06410261: Recruiting NA study of Multiple Sclerosis, sponsored by University of Illinois at Chicago.

NCT06410261 is a NA study of Multiple Sclerosis that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 24 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06410261, a NA study of Multiple Sclerosis, is actively recruiting participants, sponsored by University of Illinois at Chicago.

RECRUITING
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

Approximately 50% of people with multiple sclerosis (MS) use a wheelchair within 30 years of the initial diagnosis. Wheelchair use in MS is often associated with fatigue as a consequence of muscle weakness. Indeed, fatigue, a prevalent consequence of MS, often becomes debilitating and exhausts energetic resources when carrying-out tasks of daily life and/or interacting with the community, as these require ambulatory mobility. This experience of excessive fatigue has its roots in muscle weakness and results in reliance on a wheelchair for mobility, and the dependency on a wheelchair may further reduce muscular strength, particularly of the lower extremities. We propose that wheelchair users with MS can increase muscular strength through a personalized exercise rehabilitation, and this in turn will improve ambulatory performance and possibly reduce fatigue. To date, no research has examined the effects of this specific exercise rehabilitation program (GH method) on physical function and other disease-related outcomes in persons with MS who use wheelchairs as a primary mobility device.

Primary Outcome

Short Physical Performance Battery (SPPB); the performance scores range between 0 (min) and 12 (max) points, higher scores reflect better physical function

Conditions Studied

Interventions

  • BEHAVIORAL Exercise rehabilitation program

Study Locations (1)

Illinois

  • University of Illinois at Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2024-04-29
Est. Completion 2027-07-31
Phase NA
University of Illinois at Chicago

430 total trials

What NCT06410261 shows while recruiting

NCT06410261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Exercise rehabilitation program is the first listed.

NCT06410261 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT06410261 about?

NCT06410261 is a clinical study titled "Exercise Rehabilitation Program in MS Who Use Wheelchairs as a Primary Mobility Device". Approximately 50% of people with multiple sclerosis (MS) use a wheelchair within 30 years of the initial diagnosis. Wheelchair use in MS is often associated with fatigue as a consequence of muscle weakness. Indeed, fatigue, a prevalent consequence of MS, often becomes debilitating and exhausts energ...

What is the current status of trial NCT06410261?

This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2024-04-29. Estimated completion is 2027-07-31.

What conditions does trial NCT06410261 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT06410261?

The interventions under investigation include: Exercise rehabilitation program (BEHAVIORAL).

Who is sponsoring clinical trial NCT06410261?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06410261 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06410261's enrollment target sits among peer trials

24 246th of 315 higher than 63 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06410261, the US trial registry maintained by the National Library of Medicine. NCT06410261 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.